Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study

Kyaw Zin Thein; Siqing Fu; Filip Janku; Apostolia M. Tsimberidou; Sarina A. Piha-Paul; Daniel D. Karp; Jatin Shah; Denái R. Milton; Jing Gong; Selma Sulovic; Lacey McQuinn; Bettzy A. Stephen; Rivka R. Colen; Brett W. Carter; Funda Meric-Bernstam; Aung Naing

doi:10.36401/JIPO-21-20

Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study

Kyaw Zin Thein, Siqing Fu, Filip Janku, Apostolia M. Tsimberidou, Sarina A. Piha-Paul, Daniel D. Karp, Jatin Shah, Denái R. Milton, Jing Gong, Selma Sulovic, Lacey McQuinn, Bettzy A. Stephen, Rivka R. Colen, Brett W. Carter, Funda Meric-Bernstam, Aung Naing

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	10-12
Number of pages	3
Journal	Journal of Immunotherapy and Precision Oncology
Volume	5
Issue number	1
DOIs	https://doi.org/10.36401/JIPO-21-20
State	Published - Feb 2022

Keywords

Carboplatin
Metastatic solid tumors
Pemetrexed
Selective inhibitor of nuclear export (SINE)
Selinexor

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology
Cancer Research

Access to Document

10.36401/JIPO-21-20

Cite this

Thein, K. Z., Fu, S., Janku, F., Tsimberidou, A. M., Piha-Paul, S. A., Karp, D. D., Shah, J., Milton, D. R., Gong, J., Sulovic, S., McQuinn, L., Stephen, B. A., Colen, R. R., Carter, B. W., Meric-Bernstam, F., & Naing, A. (2022). Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study. Journal of Immunotherapy and Precision Oncology, 5(1), 10-12. https://doi.org/10.36401/JIPO-21-20

Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study. / Thein, Kyaw Zin; Fu, Siqing; Janku, Filip et al.
In: Journal of Immunotherapy and Precision Oncology, Vol. 5, No. 1, 02.2022, p. 10-12.

Research output: Contribution to journal › Comment/debate › peer-review

Thein, KZ, Fu, S, Janku, F, Tsimberidou, AM, Piha-Paul, SA, Karp, DD, Shah, J, Milton, DR, Gong, J, Sulovic, S, McQuinn, L, Stephen, BA, Colen, RR, Carter, BW, Meric-Bernstam, F & Naing, A 2022, 'Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study', Journal of Immunotherapy and Precision Oncology, vol. 5, no. 1, pp. 10-12. https://doi.org/10.36401/JIPO-21-20

@article{8e55075998dd4b76abb643c44bf59920,

title = "Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study",

keywords = "Carboplatin, Metastatic solid tumors, Pemetrexed, Selective inhibitor of nuclear export (SINE), Selinexor",

author = "Thein, {Kyaw Zin} and Siqing Fu and Filip Janku and Tsimberidou, {Apostolia M.} and Piha-Paul, {Sarina A.} and Karp, {Daniel D.} and Jatin Shah and Milton, {Den{\'a}i R.} and Jing Gong and Selma Sulovic and Lacey McQuinn and Stephen, {Bettzy A.} and Colen, {Rivka R.} and Carter, {Brett W.} and Funda Meric-Bernstam and Aung Naing",

note = "Funding Information: Source of Support: This study was supported by Karyopharm Therapeutics, Clinical and Translational Sciences Award [1UL1TR003167] National Institutes of Health/National Center for Advancing Translational Sciences (NIH/NCATS), and MD Anderson Cancer Support Grant [P30CA016672] National Institutes of Health/National Cancer Institute (NIH-NCI). Funding Information: Conflict of Interest: Aung Naing reports the following: research funding from NCI, EMD Serono, MedImmune, Healios Inc. Nutrition, Atterocor, Amplimmune, ARMO BioSciences, Eli Lilly, Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Merck, BMS, Pfizer, CytomX Therapeutics, Neon Therapeutics, Calithera Biosciences, TopAlliance Biosciences, Kymab, PsiOxus, Arcus Biosciences, NeoimmuneTech, ImmuneOncia, Surface Oncology; on advisory boards of CytomX Therapeutics, Novartis, Genome & Company, OncoSec KEYNOTE-695, and STCube; travel and accommodation expense from ARMO BioSciences. Jatin Shah is an employee of and stockholder of Karyopharm Therapuetics. The remaining authors have declared that they have no conflicts of interest.",

year = "2022",

month = feb,

doi = "10.36401/JIPO-21-20",

language = "English (US)",

volume = "5",

pages = "10--12",

journal = "Journal of Immunotherapy and Precision Oncology",

issn = "2666-2345",

publisher = "Innovative Healthcare Institute",

number = "1",

}

TY - JOUR

T1 - Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors

T2 - Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study

AU - Thein, Kyaw Zin

AU - Fu, Siqing

AU - Janku, Filip

AU - Tsimberidou, Apostolia M.

AU - Piha-Paul, Sarina A.

AU - Karp, Daniel D.

AU - Shah, Jatin

AU - Milton, Denái R.

AU - Gong, Jing

AU - Sulovic, Selma

AU - McQuinn, Lacey

AU - Stephen, Bettzy A.

AU - Colen, Rivka R.

AU - Carter, Brett W.

AU - Meric-Bernstam, Funda

AU - Naing, Aung

N1 - Funding Information: Source of Support: This study was supported by Karyopharm Therapeutics, Clinical and Translational Sciences Award [1UL1TR003167] National Institutes of Health/National Center for Advancing Translational Sciences (NIH/NCATS), and MD Anderson Cancer Support Grant [P30CA016672] National Institutes of Health/National Cancer Institute (NIH-NCI). Funding Information: Conflict of Interest: Aung Naing reports the following: research funding from NCI, EMD Serono, MedImmune, Healios Inc. Nutrition, Atterocor, Amplimmune, ARMO BioSciences, Eli Lilly, Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Merck, BMS, Pfizer, CytomX Therapeutics, Neon Therapeutics, Calithera Biosciences, TopAlliance Biosciences, Kymab, PsiOxus, Arcus Biosciences, NeoimmuneTech, ImmuneOncia, Surface Oncology; on advisory boards of CytomX Therapeutics, Novartis, Genome & Company, OncoSec KEYNOTE-695, and STCube; travel and accommodation expense from ARMO BioSciences. Jatin Shah is an employee of and stockholder of Karyopharm Therapuetics. The remaining authors have declared that they have no conflicts of interest.

PY - 2022/2

Y1 - 2022/2

KW - Carboplatin

KW - Metastatic solid tumors

KW - Pemetrexed

KW - Selective inhibitor of nuclear export (SINE)

KW - Selinexor

UR - http://www.scopus.com/inward/record.url?scp=85131644726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85131644726&partnerID=8YFLogxK

U2 - 10.36401/JIPO-21-20

DO - 10.36401/JIPO-21-20

M3 - Comment/debate

AN - SCOPUS:85131644726

SN - 2666-2345

VL - 5

SP - 10

EP - 12

JO - Journal of Immunotherapy and Precision Oncology

JF - Journal of Immunotherapy and Precision Oncology

IS - 1

ER -

Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this